Active Ingredient History
Cabozantinib (development code name XL184; marketed under the trade name Cometriq) is an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression. Cabozantinib was granted orphan drug status by the U.S. Food and Drug Administration (FDA) in January 2011. It is currently undergoing clinical trials for the treatment of prostate, bladder, ovarian, brain, melanoma, breast, non-small cell lung, pancreatic, hepatocellular and kidney cancers. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Carcinoma, Renal Cell (approved 2016)
Adenocarcinoma (Phase 2)
Adrenal Gland Neoplasms (Phase 2)
Adrenocortical Carcinoma (Phase 2)
Anemia (Phase 1)
Astrocytoma (Phase 2)
Bile Duct Neoplasms (Phase 2)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoid Tumor (Phase 3)
Carcinoma (Phase 3)
Carcinoma, Hepatocellular (Phase 4)
Carcinoma, Merkel Cell (Phase 2)
Carcinoma, Neuroendocrine (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Renal Cell (Phase 3)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 3)
Carcinosarcoma (Phase 2)
Central Nervous System Neoplasms (Phase 2)
Cholangiocarcinoma (Phase 2)
Cognitive Aging (Phase 2)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 2)
Endometrial Neoplasms (Phase 2)
Esophageal Neoplasms (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Gallbladder Neoplasms (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Gliosarcoma (Phase 1/Phase 2)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 1/Phase 2)
Healthy Volunteers (Phase 1)
Hepatoblastoma (Phase 2)
HIV Infections (Phase 1)
Hodgkin Disease (Phase 1)
Hypopharyngeal Neoplasms (Phase 2)
Intestinal Neoplasms (Phase 2)
Kidney (Phase 2)
Kidney Failure, Chronic (Phase 1)
Kidney Neoplasms (Phase 2)
Laryngeal Neoplasms (Phase 2)
Leiomyosarcoma (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Leukemia, Myeloid, Acute (Phase 1)
Leukemia, Myeloid, Chronic-Phase (Phase 1)
Leukemia, Myelomonocytic, Chronic (Phase 1)
Liver Cirrhosis (Phase 2)
Liver Diseases (Phase 1)
Liver Neoplasms (Phase 2)
Liver Transplantation (Phase 2)
Lung Neoplasms (Phase 3)
Lymphoma (Phase 1)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Non-Hodgkin (Phase 1)
Melanoma (Phase 2)
Mesothelioma (Phase 1)
Mesothelioma, Malignant (Phase 1)
Mouth Neoplasms (Phase 2)
Multiple Myeloma (Phase 1/Phase 2)
Myelodysplastic Syndromes (Phase 1)
Myeloproliferative Disorders (Phase 1)
Neoplasm Metastasis (Phase 3)
Neoplasms ()
Neoplasms, Germ Cell and Embryonal (Phase 2)
Neuroblastoma (Phase 2)
Neuroendocrine Tumors (Phase 3)
Neurofibroma (Phase 2)
Neurofibroma, Plexiform (Phase 2)
Neurofibromatoses (Phase 2)
Oropharyngeal Neoplasms (Phase 2)
Osteosarcoma (Phase 2)
Ovarian Neoplasms (Phase 2)
Pain (Phase 3)
Pancreatic Neoplasms (Phase 3)
Paraganglioma (Phase 2)
Penile Neoplasms (Phase 2)
Pheochromocytoma (Phase 2)
Primary Myelofibrosis (Phase 1)
Prostatic Neoplasms (Phase 3)
Rectal Neoplasms (Phase 2)
Rhabdomyosarcoma (Phase 2)
Salivary Gland Neoplasms (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Alveolar Soft Part (Phase 2)
Sarcoma, Clear Cell (Phase 2)
Sarcoma, Ewing (Phase 2)
Sarcoma, Kaposi (Phase 1)
Seminoma (Phase 2)
Skin Neoplasms (Phase 2)
Small Cell Lung Carcinoma (Phase 1)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 2)
Testicular Neoplasms (Phase 2)
Thyroid Cancer, Papillary (Phase 2)
Thyroid Carcinoma, Anaplastic (Phase 2)
Triple Negative Breast Neoplasms (Phase 1/Phase 2)
Ureteral Neoplasms (Phase 3)
Urethral Neoplasms (Phase 3)
Urinary Bladder Neoplasms (Phase 3)
Uterine Cervical Neoplasms (Phase 2)
Uterine Neoplasms (Phase 2)
Vulvar Neoplasms (Phase 2)
Wilms Tumor (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
